July 18, 2026
Bad cholesterol, hot comments
FDA approves new kind of cholesterol pill
New cholesterol pill drops and the comments instantly turn into a science-food fight
TLDR: The FDA approved the first pill version of a cholesterol-lowering drug that used to be available as injections only, potentially making treatment easier for many adults. Commenters split between “this is genuinely useful” and “hold on, it’s not totally new,” with side quests into chemistry flexing and cholesterol skepticism.
The FDA just approved Lipfendra, a once-a-day pill for lowering “bad” cholesterol, and the biggest gasp from the crowd was basically: wait, this used to be a shot? That’s the real plot twist here. This isn’t the first medicine in this family, as several commenters rushed to point out — it’s the first oral version, meaning people who needed injections may now have a pill option instead. For a disease that often has no obvious symptoms until it becomes a heart attack or stroke problem, commenters seemed to agree that making treatment easier could be a very big deal.
But of course, the internet could not simply say “nice.” One camp immediately went full explainer mode, posting mini textbook summaries about how these proteins work, while another jumped in with the classic correction: “not really a new kind of pharmaceutical” — just a new form factor. Translation: don’t call it revolutionary without the footnotes. Then the chemistry nerds arrived to hype the molecule itself as “quite a beast,” turning the thread into a surprise fan club for drug synthesis.
And then came the health debate. One commenter asked the question that always lights up a room: is high cholesterol a direct villain, or more of a signal that something else is wrong? That opened the door to the familiar tension between mainstream treatment optimism and “are we sure we understand this correctly?” skepticism. So yes, the FDA approved a pill — but the comments approved a full-on cholesterol cage match.
Key Points
- •The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to reduce LDL cholesterol in adults with hypercholesterolemia, including those with HeFH.
- •Lipfendra is approved as an adjunct to diet and exercise and is taken once daily as an oral tablet.
- •Before this approval, PCSK9 inhibitors were only available as injectable therapies.
- •The drug’s efficacy and safety were evaluated in two randomized, double-blind, placebo-controlled trials involving 3,207 adults on maximally tolerated statin therapy.
- •In the first trial, Lipfendra reduced LDL-C by an average of 56% at Week 24 versus placebo in adults with established ASCVD or high ASCVD risk.